185 related articles for article (PubMed ID: 23471415)
1. Optimized siRNA-PEG conjugates for extended blood circulation and reduced urine excretion in mice.
Iversen F; Yang C; Dagnæs-Hansen F; Schaffert DH; Kjems J; Gao S
Theranostics; 2013; 3(3):201-9. PubMed ID: 23471415
[TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
[TBL] [Abstract][Full Text] [Related]
3. Design of a Novel PEGylated Liposomal Vector for Systemic Delivery of siRNA to Solid Tumors.
Song F; Sakurai N; Okamoto A; Koide H; Oku N; Dewa T; Asai T
Biol Pharm Bull; 2019; 42(6):996-1003. PubMed ID: 31155597
[TBL] [Abstract][Full Text] [Related]
4. Surface De-PEGylation Controls Nanoparticle-Mediated siRNA Delivery
Zhu X; Tao W; Liu D; Wu J; Guo Z; Ji X; Bharwani Z; Zhao L; Zhao X; Farokhzad OC; Shi J
Theranostics; 2017; 7(7):1990-2002. PubMed ID: 28638484
[TBL] [Abstract][Full Text] [Related]
5. Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life.
Sato A; Choi SW; Hirai M; Yamayoshi A; Moriyama R; Yamano T; Takagi M; Kano A; Shimamoto A; Maruyama A
J Control Release; 2007 Oct; 122(3):209-16. PubMed ID: 17583369
[TBL] [Abstract][Full Text] [Related]
6. Gene silencing efficiency of siRNA-PEG conjugates: effect of PEGylation site and PEG molecular weight.
Jung S; Lee SH; Mok H; Chung HJ; Park TG
J Control Release; 2010 Jun; 144(3):306-13. PubMed ID: 20206653
[TBL] [Abstract][Full Text] [Related]
7. Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging.
Merkel OM; Librizzi D; Pfestroff A; Schurrat T; Buyens K; Sanders NN; De Smedt SC; Béhé M; Kissel T
J Control Release; 2009 Sep; 138(2):148-59. PubMed ID: 19463870
[TBL] [Abstract][Full Text] [Related]
8. Cationic Mucic Acid Polymer-Based siRNA Delivery Systems.
Pan DW; Davis ME
Bioconjug Chem; 2015 Aug; 26(8):1791-803. PubMed ID: 26154102
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial optimization of PEG architecture and hydrophobic content improves ternary siRNA polyplex stability, pharmacokinetics, and potency in vivo.
Werfel TA; Jackson MA; Kavanaugh TE; Kirkbride KC; Miteva M; Giorgio TD; Duvall C
J Control Release; 2017 Jun; 255():12-26. PubMed ID: 28366646
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte-Targeted Delivery of siRNA Polyplex with PEG-Modified Lactosylated Dendrimer/Cyclodextrin Conjugates for Transthyretin-Related Amyloidosis Therapy.
Hayashi Y; Higashi T; Motoyama K; Jono H; Ando Y; Onodera R; Arima H
Biol Pharm Bull; 2019; 42(10):1679-1688. PubMed ID: 31582656
[TBL] [Abstract][Full Text] [Related]
11. Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene‑silencing effects and siRNA biodistribution in mice.
Hattori Y; Tamaki K; Sakasai S; Ozaki KI; Onishi H
Mol Med Rep; 2020 Nov; 22(5):4183-4196. PubMed ID: 33000194
[TBL] [Abstract][Full Text] [Related]
12. PEGylated cyclodextrins as novel siRNA nanosystems: correlations between polyethylene glycol length and nanoparticle stability.
Godinho BM; Ogier JR; Quinlan A; Darcy R; Griffin BT; Cryan JF; O'Driscoll CM
Int J Pharm; 2014 Oct; 473(1-2):105-12. PubMed ID: 24992319
[TBL] [Abstract][Full Text] [Related]
13. In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.
Sasayama Y; Hasegawa M; Taguchi E; Kubota K; Kuboyama T; Naoi T; Yabuuchi H; Shimai N; Asano M; Tokunaga A; Ishii T; Enokizono J
J Control Release; 2019 Oct; 311-312():245-256. PubMed ID: 31505222
[TBL] [Abstract][Full Text] [Related]
14. Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers.
Miteva M; Kirkbride KC; Kilchrist KV; Werfel TA; Li H; Nelson CE; Gupta MK; Giorgio TD; Duvall CL
Biomaterials; 2015 Jan; 38():97-107. PubMed ID: 25453977
[TBL] [Abstract][Full Text] [Related]
15. Grafting of poly(ethylene glycol) to poly-lysine augments its lifetime in blood circulation and accumulation in tumors without loss of the ability to associate with siRNA.
Kano A; Moriyama K; Yamano T; Nakamura I; Shimada N; Maruyama A
J Control Release; 2011 Jan; 149(1):2-7. PubMed ID: 20005270
[TBL] [Abstract][Full Text] [Related]
16. Post-PEGylation of siRNA Lipo-oligoamino Amide Polyplexes Using Tetra-glutamylated Folic Acid as Ligand for Receptor-Targeted Delivery.
Müller K; Kessel E; Klein PM; Höhn M; Wagner E
Mol Pharm; 2016 Jul; 13(7):2332-45. PubMed ID: 27177200
[TBL] [Abstract][Full Text] [Related]
17. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
18. Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol).
Liu L; Zheng M; Librizzi D; Renette T; Merkel OM; Kissel T
Mol Pharm; 2016 Jan; 13(1):134-43. PubMed ID: 26641134
[TBL] [Abstract][Full Text] [Related]
19. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
20. Zwitterionic Nanocarrier Surface Chemistry Improves siRNA Tumor Delivery and Silencing Activity Relative to Polyethylene Glycol.
Jackson MA; Werfel TA; Curvino EJ; Yu F; Kavanaugh TE; Sarett SM; Dockery MD; Kilchrist KV; Jackson AN; Giorgio TD; Duvall CL
ACS Nano; 2017 Jun; 11(6):5680-5696. PubMed ID: 28548843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
